API
< Back to all clusters
[HEALTH] · EU · 4 sources

started · updated

European Commission approves trofinetide for Rett syndrome

The European Commission has authorized the marketing of trofinetide, branded as Daybu, for the treatment of neurobehavioral symptoms in adults and pediatric patients aged five and older with Rett syndrome. Developed by Acadia Pharmaceuticals, this represents the first and currently only therapy specifically approved for this indication within the European Union.

Rett syndrome is a rare and severe genetic disorder characterized by a complex neurobehavioral profile, including a regressive phase marked by the rapid loss of language and communication skills, as well as sleep disturbances and anxiety. The approval was primarily based on results from the Phase 3 LAVENDER study.

The authorization is valid across the 27 EU member states and includes Iceland, Liechtenstein, and Norway through the European Economic Area. Following this regulatory approval, Acadia Pharmaceuticals must now initiate national procedures for pricing and reimbursement in individual countries to ensure patient access through various healthcare systems.

Entities

Acadia Pharmaceuticals · European Commission · trofinetide